Singapore, Aug. 12 -- Thermo Fisher Scientific, the world leader in serving science, has received approval from the US Food and Drug Administration (FDA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS(R)(zongertinib tablets), a tyrosine kinase inhibitor (TKI), developed by Boehringer Ingelheim.

The test allows clinicians and pathologists to assess if non-small cell lung cancer (NSCLC) tumours harbor human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations.

The US FDA approved HERNEXEOS on August 8, 2025 as the first and only orally administered targeted therapy for adult patients with unresectable or metastatic non-sq...